Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

NCT03817515 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

PEComa, Malignant
TSC1
TSC2
mTOR Pathway Abberation

Interventions

DRUG: ABI-009

Sponsor

Aadi Bioscience, Inc.